Which has stronger valuation & earnings, VEEV or MASI?

Veeva Systems has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veeva Systems $3.32B 7.50 $908.91M $5.61 27.31 Masimo $1.56B 6.05 -$151.50M -$10.54 N/A

Is VEEV or MASI more profitable?

Veeva Systems has a net margin of 28.37% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Veeva Systems' return on equity. Company Net Margins Return on Equity Return on Assets Veeva Systems 28.37% 13.72% 11.31% Masimo 4.90% 31.33% 13.93%

Which has preferable earnings and valuation, MASI or DXCM?

DexCom has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Masimo $1.56B 6.05 -$151.50M -$10.54 N/A DexCom $4.82B 5.80 $836.30M $2.34 30.97

Is MASI or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Masimo's net margin of 4.90%. DexCom's return on equity of 33.33% beat Masimo's return on equity. Company Net Margins Return on Equity Return on Assets Masimo 4.90% 31.33% 13.93% DexCom 19.31% 33.33% 13.19%

Which has higher earnings & valuation, RMD or MASI?

ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.54B 4.95 $1.40B $10.37 18.21 Masimo $1.56B 6.05 -$151.50M -$10.54 N/A

Is RMD or MASI more profitable?

ResMed has a net margin of 27.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat ResMed's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Masimo 4.90% 31.33% 13.93%

Which has better valuation & earnings, MASI or STE?

STERIS has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Masimo $1.56B 6.05 -$151.50M -$10.54 N/A STERIS $5.94B 3.33 $782.30M $7.93 25.55

Is MASI or STE more profitable?

STERIS has a net margin of 13.18% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat STERIS's return on equity. Company Net Margins Return on Equity Return on Assets Masimo 4.90% 31.33% 13.93% STERIS 13.18% 14.15% 9.52%

Masimo (MASI) Competitors

$179.95 0.00 (0.00%)

As of 06/10/2026

Compare

MASI vs. AMN, VEEV, DXCM, RMD, and STE

Should you buy Masimo stock or one of its competitors? MarketBeat compares Masimo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Masimo include AMN Healthcare Services (AMN), Veeva Systems (VEEV), DexCom (DXCM), ResMed (RMD), and STERIS (STE). These companies are all part of the "medical" sector.

How does Masimo compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Masimo (NASDAQ:MASI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, AMN Healthcare Services had 5 more articles in the media than Masimo. MarketBeat recorded 5 mentions for AMN Healthcare Services and 0 mentions for Masimo. AMN Healthcare Services' average media sentiment score of 0.35 beat Masimo's score of 0.22 indicating that AMN Healthcare Services is being referred to more favorably in the media.

Company	Overall Sentiment
AMN Healthcare Services	Neutral
Masimo	Neutral

AMN Healthcare Services has higher revenue and earnings than Masimo. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Masimo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$3.42B	0.35	-$95.70M	-$0.87	N/A
Masimo	$1.56B	6.05	-$151.50M	-$10.54	N/A

AMN Healthcare Services presently has a consensus price target of $25.29, indicating a potential downside of 18.47%. Masimo has a consensus price target of $180.40, indicating a potential upside of 0.25%. Given Masimo's higher probable upside, analysts plainly believe Masimo is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Masimo has a net margin of 4.90% compared to AMN Healthcare Services' net margin of -0.95%. Masimo's return on equity of 31.33% beat AMN Healthcare Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-0.95%	18.01%	5.19%
Masimo	4.90%	31.33%	13.93%

AMN Healthcare Services has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Masimo has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market.

Summary

AMN Healthcare Services and Masimo tied by winning 8 of the 16 factors compared between the two stocks.

How does Masimo compare to Veeva Systems?

Veeva Systems (NYSE:VEEV) and Masimo (NASDAQ:MASI) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

88.2% of Veeva Systems shares are held by institutional investors. Comparatively, 86.0% of Masimo shares are held by institutional investors. 10.6% of Veeva Systems shares are held by company insiders. Comparatively, 9.7% of Masimo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Veeva Systems currently has a consensus target price of $250.96, indicating a potential upside of 63.81%. Masimo has a consensus target price of $180.40, indicating a potential upside of 0.25%. Given Veeva Systems' stronger consensus rating and higher probable upside, analysts plainly believe Veeva Systems is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veeva Systems	1 Sell rating(s)	8 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	2.63
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Veeva Systems has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Veeva Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veeva Systems	$3.32B	7.50	$908.91M	$5.61	27.31
Masimo	$1.56B	6.05	-$151.50M	-$10.54	N/A

Veeva Systems has a net margin of 28.37% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat Veeva Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veeva Systems	28.37%	13.72%	11.31%
Masimo	4.90%	31.33%	13.93%

Veeva Systems has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Masimo has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, Veeva Systems had 22 more articles in the media than Masimo. MarketBeat recorded 22 mentions for Veeva Systems and 0 mentions for Masimo. Veeva Systems' average media sentiment score of 1.32 beat Masimo's score of 0.22 indicating that Veeva Systems is being referred to more favorably in the media.

Company	Overall Sentiment
Veeva Systems	Positive
Masimo	Neutral

Summary

Veeva Systems beats Masimo on 13 of the 16 factors compared between the two stocks.

How does Masimo compare to DexCom?

Masimo (NASDAQ:MASI) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, DexCom had 25 more articles in the media than Masimo. MarketBeat recorded 25 mentions for DexCom and 0 mentions for Masimo. DexCom's average media sentiment score of 1.14 beat Masimo's score of 0.22 indicating that DexCom is being referred to more favorably in the news media.

Company	Overall Sentiment
Masimo	Neutral
DexCom	Positive

DexCom has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.56B	6.05	-$151.50M	-$10.54	N/A
DexCom	$4.82B	5.80	$836.30M	$2.34	30.97

DexCom has a net margin of 19.31% compared to Masimo's net margin of 4.90%. DexCom's return on equity of 33.33% beat Masimo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
DexCom	19.31%	33.33%	13.19%

Masimo presently has a consensus price target of $180.40, indicating a potential upside of 0.25%. DexCom has a consensus price target of $84.83, indicating a potential upside of 17.06%. Given DexCom's stronger consensus rating and higher possible upside, analysts plainly believe DexCom is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DexCom	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	3 Strong Buy rating(s)	2.92

Masimo has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 0.3% of DexCom shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

DexCom beats Masimo on 14 of the 17 factors compared between the two stocks.

How does Masimo compare to ResMed?

ResMed (NYSE:RMD) and Masimo (NASDAQ:MASI) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

ResMed presently has a consensus price target of $273.00, suggesting a potential upside of 44.57%. Masimo has a consensus price target of $180.40, suggesting a potential upside of 0.25%. Given ResMed's stronger consensus rating and higher possible upside, equities analysts clearly believe ResMed is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.67
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

55.0% of ResMed shares are owned by institutional investors. Comparatively, 86.0% of Masimo shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 9.7% of Masimo shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ResMed has a beta of 0.8, indicating that its share price is 20% less volatile than the broader market. Comparatively, Masimo has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

ResMed has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.54B	4.95	$1.40B	$10.37	18.21
Masimo	$1.56B	6.05	-$151.50M	-$10.54	N/A

ResMed has a net margin of 27.44% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Masimo	4.90%	31.33%	13.93%

In the previous week, ResMed had 14 more articles in the media than Masimo. MarketBeat recorded 14 mentions for ResMed and 0 mentions for Masimo. ResMed's average media sentiment score of 0.89 beat Masimo's score of 0.22 indicating that ResMed is being referred to more favorably in the media.

Company	Overall Sentiment
ResMed	Positive
Masimo	Neutral

Summary

ResMed beats Masimo on 12 of the 17 factors compared between the two stocks.

How does Masimo compare to STERIS?

Masimo (NASDAQ:MASI) and STERIS (NYSE:STE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

STERIS has higher revenue and earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.56B	6.05	-$151.50M	-$10.54	N/A
STERIS	$5.94B	3.33	$782.30M	$7.93	25.55

Masimo presently has a consensus price target of $180.40, indicating a potential upside of 0.25%. STERIS has a consensus price target of $278.00, indicating a potential upside of 37.22%. Given STERIS's stronger consensus rating and higher probable upside, analysts clearly believe STERIS is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

STERIS has a net margin of 13.18% compared to Masimo's net margin of 4.90%. Masimo's return on equity of 31.33% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	4.90%	31.33%	13.93%
STERIS	13.18%	14.15%	9.52%

86.0% of Masimo shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 1.1% of STERIS shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, STERIS had 13 more articles in the media than Masimo. MarketBeat recorded 13 mentions for STERIS and 0 mentions for Masimo. STERIS's average media sentiment score of 1.10 beat Masimo's score of 0.22 indicating that STERIS is being referred to more favorably in the news media.

Company	Overall Sentiment
Masimo	Neutral
STERIS	Positive

Masimo has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, STERIS has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Summary

STERIS beats Masimo on 11 of the 16 factors compared between the two stocks.

Get Masimo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MASI vs. The Competition

Export

Metric	Masimo	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.42B	$6.99B	$6.41B	$12.60B
Dividend Yield	N/A	1.21%	2.67%	5.69%
P/E Ratio	-17.07	47.51	24.46	24.45
Price / Sales	6.05	86.64	554.57	123.58
Price / Cash	38.74	25.19	43.94	55.48
Price / Book	13.40	7.17	10.71	6.59
Net Income	-$151.50M	$159.20M	$3.57B	$337.29M
7 Day Performance	N/A	-0.77%	0.66%	0.59%
1 Month Performance	0.64%	4.95%	3.66%	4.47%
1 Year Performance	10.55%	5.63%	28.47%	31.21%

Masimo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MASI Masimo	1.4679 of 5 stars	$179.95 flat	$180.40 +0.3%	N/A	$9.42B	$1.56B	N/A	2,200
AMN AMN Healthcare Services	1.7017 of 5 stars	$30.88 +0.2%	$25.29 -18.1%	+47.9%	$1.19B	$2.73B	N/A	2,664	Insider Trade
VEEV Veeva Systems	4.8817 of 5 stars	$162.09 +1.6%	$250.96 +54.8%	-45.1%	$25.92B	$3.20B	28.89	7,928	Positive News
DXCM DexCom	4.6038 of 5 stars	$74.22 -1.5%	$84.83 +14.3%	-13.0%	$29.08B	$4.66B	31.72	11,000	Positive News Analyst Forecast Insider Trade
RMD ResMed	4.9395 of 5 stars	$193.05 -0.9%	$279.82 +44.9%	-25.5%	$28.25B	$5.15B	18.62	10,600	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MASI) was last updated on 6/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Masimo (MASI) Competitors

MASI vs. AMN, VEEV, DXCM, RMD, and STE

How does Masimo compare to AMN Healthcare Services?

Summary

How does Masimo compare to Veeva Systems?

Summary

How does Masimo compare to DexCom?

Summary

How does Masimo compare to ResMed?

Summary

How does Masimo compare to STERIS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI vs. The Competition

Masimo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Masimo (MASI) Competitors

MASI vs. AMN, VEEV, DXCM, RMD, and STE

How does Masimo compare to AMN Healthcare Services?

Do insiders and institutionals have more ownership in AMN or MASI?

Does the media refer more to AMN or MASI?

Which has stronger earnings and valuation, AMN or MASI?

Do analysts rate AMN or MASI?

Is AMN or MASI more profitable?

Which has more volatility and risk, AMN or MASI?

Summary

How does Masimo compare to Veeva Systems?

Do institutionals & insiders believe in VEEV or MASI?

Do analysts recommend VEEV or MASI?

Which has stronger valuation & earnings, VEEV or MASI?

Is VEEV or MASI more profitable?

Which has more volatility and risk, VEEV or MASI?

Does the media favor VEEV or MASI?

Summary

How does Masimo compare to DexCom?

Does the media prefer MASI or DXCM?

Which has preferable earnings and valuation, MASI or DXCM?

Is MASI or DXCM more profitable?

Do analysts prefer MASI or DXCM?

Which has more risk & volatility, MASI or DXCM?

Do institutionals and insiders believe in MASI or DXCM?

Summary

How does Masimo compare to ResMed?

Do analysts rate RMD or MASI?

Do insiders & institutionals hold more shares of RMD or MASI?

Which has more risk & volatility, RMD or MASI?

Which has higher earnings & valuation, RMD or MASI?

Is RMD or MASI more profitable?

Does the media favor RMD or MASI?

Summary

How does Masimo compare to STERIS?

Which has better valuation & earnings, MASI or STE?

Do analysts recommend MASI or STE?

Is MASI or STE more profitable?

Do insiders and institutionals believe in MASI or STE?

Does the media refer more to MASI or STE?

Which has more volatility & risk, MASI or STE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MASI vs. The Competition

Masimo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools